STOCK TITAN

PHARM - PHARM STOCK NEWS

Welcome to our dedicated news page for PHARM (Ticker: PHARM), a resource for investors and traders seeking the latest updates and insights on PHARM.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PHARM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PHARM's position in the market.

Rhea-AI Summary
Pharming Group N.V. announces participation in investor conferences in February, including Oppenheimer 34th Annual Healthcare Life Sciences Virtual Conference and UBS European Healthcare Conference. CEO Sijmen de Vries to present at the Oppenheimer conference on February 13. Webcast and replay available on Pharming's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Pharming Group N.V. (PHARM) expects 10% growth in RUCONEST® revenue, significantly exceeding prior guidance. Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end. Total revenues expected to increase by 19% to approximately US$245 million for full year 2023. The company aims to further develop its rare disease pipeline and footprint, seeking to significantly expand the leniolisib market opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pharming Group N.V. (PHARM/Nasdaq: PHAR) expands its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS). The Phase 2 clinical trial for leniolisib in PIDs with immune dysregulation linked to PI3Kẟ signaling is planned to start in 2Q 2024. The trial aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and explore clinical efficacy in approximately 12 patients, with the potential to inform a subsequent Phase 3 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Pharming Group N.V. (PHARM) announces the dosing of the first patient in the Phase III pediatric clinical trial evaluating a new pediatric granulated formulation of leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children ages one to six years, with activated phosphoinositide 3-kinase delta syndrome (APDS). The multinational study aims to evaluate the safety, tolerability, and efficacy of leniolisib in 15 children with a confirmed APDS diagnosis, using a specific, pediatric granulated formulation of the drug. The primary and secondary endpoints of the trial align with previous leniolisib Phase II/III APDS trials for older patients. The company's Chief Medical Officer expressed commitment to providing new treatment options for younger pediatric patients with APDS, aiming to facilitate additional regulatory filings to expand the potential patient population benefiting from this treatment. This is the second pediatric clinical trial launched by Pharming this year for the study of leniolisib in pediatric patients with APDS, following the FDA approval of leniolisib for the treatment of APDS in adult and pediatric patients 12 years of age and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Pharming Group N.V. (PHARM) Receives Day 180 Second List of Outstanding Issues from EMA for Leniolisib MAA, Expects CHMP Opinion in Q1 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pharming Group N.V. announces its participation in two investor conferences in November. Anurag Relan, Chief Medical Officer, will participate in a fireside chat and Q&A session at the Stifel 2023 Healthcare Conference on November 14. Sijmen de Vries, CEO, will present at the Jefferies London Healthcare Conference on November 15.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Pharming Group reports Q3 2023 financial results, with revenues increasing 23% to $66.7M compared to Q3 2022. RUCONEST® revenue increased 11% in Q3 2023 to $60.2M. Joenja® launch continues to show strength with 63 patients on paid therapy and $6.5M revenue. Overall cash and securities at $199.2M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Pharming Group N.V. will report its preliminary Q3 2023 financial results on October 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Pharming Group N.V. (Euronext: PHARM/Nasdaq: PHAR) announces the adoption of all proposals at the Extraordinary General Meeting of Shareholders, including the appointment of Dr. Richard Peters as Non-Executive director and Chair of the Board of Directors. Shareholders also approved the annual fee increase for the Chair. The Company expresses gratitude to outgoing Chairman Paul Sekhri and looks forward to Dr. Peters' leadership in achieving strategic objectives and strengthening Pharming's position in the rare disease market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
PHARM

Nasdaq:PHARM

PHARM Rankings

PHARM Stock Data